Pharmaceuticals
ABVC BioPharma Receives $100,000 Milestone Payment in Vitargus Licensing Deal
ABVC BioPharma's latest milestone payment from ForSeeCon Eye Corporation strengthens a licensing agreement potentially worth $63.5 million for Vitargus®, positioning the company to capitalize on the multi-billion dollar global vitreous substitute market.
Quantum BioPharma Announces Debt Settlement, Equity Grants, and Advisor Departure
Quantum BioPharma has settled outstanding debt through share issuance, granted restricted share units tied to regulatory milestones for its Lucid MS program, and terminated an advisor agreement, reflecting strategic financial and clinical development moves.
Vaginal Estrogen Tablets Show No Increased Stroke Risk for Postmenopausal Women with Prior Stroke History
A Danish registry study found vaginal estrogen tablets do not increase recurrent stroke risk in postmenopausal women with prior strokes, offering reassurance for safe symptom management in this high-risk population.
ReAlta Life Sciences Gains EMA Orphan Drug Designation for Graft-Versus-Host Disease Treatment
ReAlta Life Sciences received European Medicines Agency Orphan Drug Designation for its drug pegtarazimod, advancing a novel dual-targeting treatment approach for steroid-refractory acute graft-versus-host disease that addresses critical unmet medical needs.
Nutriband Advances Fentanyl Patch Development with FDA Meeting as CEO Pursues Presidential Nomination
Nutriband Inc. progresses its abuse-deterrent fentanyl patch AVERSA™ through FDA regulatory pathways while maintaining leadership continuity during CEO Gareth Sheridan's temporary departure for Irish presidential candidacy.
Bank of America Downgrades Novavax to Underperform Citing Long-Term Growth Concerns
Bank of America downgraded Novavax to Underperform due to concerns about the vaccine maker's sustainable growth prospects amid shifting COVID-19 variants and heightened FDA regulatory requirements.
Incannex Healthcare's IHL-42X Shows Promising Phase 2 Results for Sleep Apnea Treatment
Incannex Healthcare Inc. reports significant progress with its IHL-42X treatment for obstructive sleep apnea, achieving up to 83% reduction in apnea events with strong patient-reported outcomes, positioning the company for potential market entry while strengthening its financial position.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.
Nutriband Inc. to Showcase AVERSA(TM) Technology at Emerging Growth Conference
Nutriband Inc. (NASDAQ: NTRB) will present its AVERSA(TM) abuse-deterrent technology at the Emerging Growth Conference, highlighting its potential to revolutionize transdermal pharmaceutical products.
Soligenix Inc. Receives FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix Inc. has been granted FDA orphan drug designation for dusquetide, a significant step forward in treating Behçet’s Disease, highlighting the potential for new therapies in rare diseases.
Fifty 1 Labs and BioSpark AI Pioneer AI-Driven Drug Repurposing with Major Database Achievement
Fifty 1 Labs and BioSpark AI have created a structured database from over 10,000 case reports, marking a significant advancement in AI-driven drug repurposing for complex conditions.
CNS Pharmaceuticals Inc. to Showcase Innovative Cancer Treatments at Webull Financial Biotech/MedTech Webinar
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) will present its groundbreaking cancer treatment research at the upcoming Webull Financial Corporate Connect Webinar Series, highlighting the potential of its drug candidate TPI 287 in treating brain and central nervous system cancers.
Soligenix Inc. Reports Q2 2025 Results with Progress in Rare Disease Treatments
Soligenix Inc. highlights advancements in its rare disease treatment pipeline, including progress in psoriasis and cutaneous T-cell lymphoma therapies, amidst a widened net loss in Q2 2025.
CNS Pharmaceuticals Inc. Advances TPI 287 Toward Phase 2 GBM Trial Amid Improved Financials
CNS Pharmaceuticals Inc. reports a slight improvement in Q2 2025 financials, with reduced net losses and increased R&D expenses as it prepares for a Phase 2 trial of TPI 287 for glioblastoma multiforme, highlighting the drug's potential to cross the blood-brain barrier and treat CNS tumors.
Alpha Cognition Inc. Advances Alzheimer's Treatment with ZUNVEYL, Secures Key Regulatory Milestones
Alpha Cognition Inc. reports significant progress in the commercialization of ZUNVEYL for Alzheimer's disease, highlighting early adoption in the U.S. long-term care market and a key regulatory achievement in China.
Public Health Groups Alert New York to Counterfeit HIV Medication Crisis
Public health organizations have filed a complaint against a New York pharmacy for allegedly dispensing counterfeit HIV medication, posing a severe risk to patients and public health.
Nutriband Inc. CEO Temporarily Steps Down to Pursue Irish Presidency, Company Focuses on AVERSA Fentanyl Development
Nutriband Inc. announces CEO Gareth Sheridan's temporary departure to run for Irish Presidency, with Chairman Serguei Melnik stepping in, as the company advances its AVERSA Fentanyl abuse-deterrent opioid patch towards FDA approval.
Alliance Global Partners Raises Soligenix Inc. Price Target Amid Clinical Progress
Alliance Global Partners has increased Soligenix Inc.'s price target to $10 per share, citing advancements in its clinical programs for rare diseases.
Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS
Quantum BioPharma Ltd. has taken a significant step towards clinical trials for its oral Lucid-MS treatment for multiple sclerosis by partnering with a leading contract development and manufacturing organization.
Creative Biolabs Introduces AI-Powered Solution to Revolutionize Drug Discovery
Creative Biolabs has launched an AI-powered end-to-end drug discovery solution aimed at addressing the challenges of high costs, failure rates, and lengthy timelines in drug R&D.
Nutriband Inc. Advances Toward FDA Approval for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
Nutriband Inc. has secured a Type C Meeting with the FDA for its AVERSA(TM) Fentanyl patch, a significant step towards introducing the world's first abuse-deterrent opioid patch to the market.
BioKey Positions Itself as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts
ABVC BioPharma's subsidiary, BioKey, leverages its Silicon Valley manufacturing facility to meet global demand for compliant drug production, highlighting the importance of local infrastructure in the face of increasing tariffs and supply chain realignments.
Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Prospects for Neurodegenerative Diseases
Annovis Bio Inc. has expanded its patent portfolio to cover a new crystalline form of buntanetap, promising improved stability and bioequivalence for treating neurodegenerative diseases like Alzheimer's and Parkinson's, with protection extending through 2046.
Nutriband Inc. Pioneers Abuse-Deterrent Technology in Response to Opioid Crisis
Nutriband Inc. is advancing its Aversa(TM) technology to combat the misuse of potent opioids like fentanyl, addressing a critical challenge in drug delivery and public health.
Quantum BioPharma Ltd. Reports Positive Phase 1 Safety Results for Lucid-MS
Quantum BioPharma Ltd. announces positive Phase 1 safety results for Lucid-MS, a potential treatment for multiple sclerosis, marking a significant step towards efficacy trials and FDA application.
Soligenix Inc. Advances in Rare Disease Therapeutics with HyBryte(TM) Platform
Soligenix Inc. (NASDAQ: SNGX) is making significant strides in the development of treatments for rare diseases, particularly with its HyBryte(TM) platform for cutaneous T-cell lymphoma, addressing a critical need for FDA-approved therapies in an underserved market.
XOMA Royalty to Acquire LAVA Therapeutics in a Deal Worth Up to $1.24 Per Share Plus Contingent Value Rights
XOMA Royalty Corporation's acquisition of LAVA Therapeutics for up to $1.24 per share plus contingent value rights marks a significant move in the biotech sector, promising to benefit shareholders and advance innovative cancer treatments.
D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation
D. Boral Capital LLC's role as the exclusive placement agent in Omeros Corporation's $22 million registered direct offering highlights the firm's pivotal position in facilitating significant financial transactions for emerging growth companies.
Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.